Momentum Back At Cipla In Q2 But Albuterol Delayed In US
Executive Summary
Cipla had a strong run across key businesses in Q2, with products like generic Sensipar retaining share in the US despite stiff competition. But launch timelines for generic albuterol in the US have been pushed back to fiscal 2021.
You may also be interested in...
Cipla To Recalibrate US Investments
Cipla is to moderate investments across its US generics R&D and specialty business, while its India business components – prescription, trade generic and consumer health – are being brought under a “single capital allocation framework.”
Cipla To Recalibrate US Investments, Partnering Plan For Specialty Business
Cipla to moderate investments across US generics R&D and specialty business, while its India business components - prescription, trade generic and consumer health - are being brought under a “single capital allocation framework.”
Cipla Reorganizes Its Executive Team
Ex-Torrent COO Arunesh Verma is to lead Cipla’s North America generics business, while the head of Cipla USA has been repositioned to lead the India prescription business, among other personnel changes.
Need a specific report? 1000+ reports available
Buy Reports
